This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    pregnancy lyme
Previous Study | Return to List | Next Study

Pregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06026969
Recruitment Status : Recruiting
First Posted : September 7, 2023
Last Update Posted : September 7, 2023
Sponsor:
Collaborators:
Clinical Trials Network for Lyme and Other Tick-Borne Diseases
Steven & Alexandra Cohen Foundation
Information provided by (Responsible Party):
Children's National Research Institute

Brief Summary:
The purpose of this pilot study is to assess the feasibility of longitudinal neurodevelopmental evaluation of fetuses and infants exposed to Lyme disease in utero. Participants with Lyme disease or Post-Treatment Lyme Disease Syndrome (PTLDS) will be recruited during pregnancy. Pregnancies will be monitored and infant development will be assessed from birth until age 18 months.

Condition or disease Intervention/treatment
Lyme Disease Post-Treatment Lyme Disease Chronic Lyme Disease Tick-Borne Infections Pregnancy Complications Child Development Other: Neurodevelopmental assessments and follow-up

Detailed Description:

Childhood neurodevelopmental outcomes following antenatal Lyme disease exposure are not yet known. This pilot study will lay the groundwork for a larger study to determine the effect of in utero exposure to Lyme disease on pregnancy and early childhood neurodevelopmental outcomes. Understanding the effects on the developing brain is essential in order to inform timely prenatal and postnatal treatments to protect the fetus exposed to Lyme disease during pregnancy. Once childhood neurodevelopmental outcomes are known, appropriate follow-up and treatment guidelines can be developed to help better support children's developmental needs.

The primary aim of this study is to assess the feasibility of longitudinal follow-up of fetuses and infants exposed to Lyme disease in utero.Lyme disease in pregnancy and the impact on the fetus/child following in utero exposure has been identified as a priority research area; this pilot study is the essential step to plan a large study that will fill this knowledge gap and make a substantial contribution to the field.

The investigators will perform a prospective pilot longitudinal cohort study of B. burgdorferi-infected parents and their in-utero-exposed fetuses/infants. Patients included in this study will have a clinical diagnosis of Lyme disease during gestation or have been diagnosed with Lyme disease and/or PTLDS within 3 years preceding pregnancy.

Pregnant participants will receive a fetal MRI and ultrasound during the second or third trimesters of gestation. The investigators will conduct optional qualitative interviews with interested participants during their 3rd trimester to gather additional data on their experiences with Lyme disease/PTLDS during pregnancy. The placenta will be collected at birth and analyzed by an experienced placental pathologist per a standard protocol. Parent and infant blood will be tested for Lyme disease serology and markers of inflammation.

Following birth, infants will receive an unsedated brain MRI and a cranial ultrasound. The investigators will complete serial developmental evaluations using standardized assessments at multiple timepoints through age 18 months and receive neurological examinations. Throughout the study, participants will also be asked to complete questionnaires including but not limited to topics such as medical history, nutrition, breastfeeding, and socioeconomic information.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Pregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure
Actual Study Start Date : July 1, 2023
Estimated Primary Completion Date : June 2025
Estimated Study Completion Date : June 2025

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Lyme disease

Pregnant participants in the "Lyme disease" cohort will meet CDC criteria for clinical and/or laboratory diagnosis of Lyme disease during pregnancy based on stage of disease. Participants will be enrolled following confirmation that they have been diagnosed by a medical professional per CDC guidelines.

Participants in this cohort may be enrolled during any trimester of pregnancy. Live-born infants will be included in the cohort and followed through age 18 months.

Other: Neurodevelopmental assessments and follow-up
All infants included in this study will receive standardized neurodevelopmental assessment and neurological examinations through age 18 months.

Post-treatment Lyme Disease Syndrome (PTLDS) or Chronic Lyme

Pregnant participants in the "PTLDS/Chronic Lyme" cohort will have been diagnosed with PTLDS/Chronic Lyme by a health care provider no less than 6 months, but no greater than 3 years, prior to enrollment. Participants will be enrolled following confirmation that they have been diagnosed by a medical professional per CDC guidelines.

Participants in this cohort may be enrolled during any trimester of pregnancy. Live-born infants will be included in the cohort and followed through age 18 months.

Other: Neurodevelopmental assessments and follow-up
All infants included in this study will receive standardized neurodevelopmental assessment and neurological examinations through age 18 months.




Primary Outcome Measures :
  1. Number of parent-infant dyads enrolled in the study through completion of their infant's 18-month follow-up visit [ Time Frame: 7/1/2023 - 6/30/2025 ]
    The primary outcome of this pilot study is to assess the feasibility of enrollment and longitudinal follow-up of Lyme-exposed dyads. Investigators will measure the number of parent-infant dyads who are eligible for participation, who participate in each study visit, and who successfully complete the study through infant age 18 months, throughout the duration of the study.


Secondary Outcome Measures :
  1. Warner Initial Developmental Evaluation (WIDEA) [ Time Frame: Child ages: 2 months, 6 months, 12 months, 18 months ]
    Infants will be evaluated at 2, 6, 12, and 18 months of age using the Warner Initial Developmental Evaluation (WIDEA). The WIDEA is a 43-item questionnaire to assess the functional domains of self-care, motor function, communication, and social cognition in young children.

  2. Ages and Stages Questionnaire (ASQ) [ Time Frame: Child ages: 2 months, 6 months, 12 months, 18 months ]
    Infants will be evaluated at 2, 6, 12, and 18 months of age using the Ages and Stages Questionnaire (ASQ). The ASQ will assess for possible developmental delays in the domains of communication, gross motor, fine motor, problem solving, and personal adaptive skills.

  3. Alberta Infant Motor Scale (AIMS) [ Time Frame: Child ages: 2 months, 6 months, 12 months, 18 months ]
    Infants will be evaluated at 2, 6, 12, and 18 months of age using the Alberta Infant Motor Scale (AIMS). The AIMS is an observational motor assessment that can be done in-person or using telehealth.

  4. Infant height [ Time Frame: All study visits between birth - 18 months of age ]
    Infants' height in centimeters will be collected at each study visit.

  5. Infant weight [ Time Frame: All study visits between birth - 18 months of age ]
    Infants' height in kilograms will be collected at each study visit.

  6. Infant head circumference [ Time Frame: Birth - 18 months of age ]
    Infants' head circumference in centimeters will be collected at each study visit.

  7. Placental tissue analysis [ Time Frame: Placenta to be collected at delivery hospital immediately after birth ]
    The placenta will be collected at birth and analyzed by an experienced placental pathologist per a standard protocol. The study team will provide the pregnant participant a letter about their study participation that they can share with their obstetrician requesting placental pathology to be performed. The study coordinator will request the paraffin embedded blocks and/or slides to be sent to Children's National for additional analysis including silver stain. Silver stain will be included to identify any spirochetes in placental tissue.

  8. Analysis of parent and infant blood [ Time Frame: Adult: during pregnancy between 20-38 weeks gestational age, and between infant age 2-8 weeks; Child: Between ages 2-8 weeks ]
    Blood will be collected at the study visit in the Lyme-exposed parent and infant to measure Lyme serology (IgM, IgG), PCR, and inflammatory cytokines. The pregnant participant will have two blood draws (one after enrollment, and one after birth) and the infant will have one blood draw at 2-8 weeks of age. The total volume of blood required for each blood draw is 2mL from the adult participant and 1.5mL from the infant.

  9. Fetal neuroimaging (Magnetic resonance imaging [MRI] and ultrasound) analysis [ Time Frame: During pregnancy between 20-38 weeks gestational age ]
    Pregnant participants will receive one fetal MRI and ultrasound examinations during the second or third trimester. Fetal MRI will be performed on a GE 1.5 T scanner (General Electric, Milwaukee, WI) using an 8-channel head coil. Fetal ultrasound and MRI will be overseen and interpreted by fetal radiologists and neuroradiologists. Images will be evaluated for any structural abnormalities and for differences in brain maturation or size. The fronto-occipital and biparietal cerebral diameters, cerebellar vermis and diameter, and corpus callosum length will be measured. Biometric measurements and estimation of fetal cortical maturation will be compared with age-expected norms. Fetal ultrasound will be used to evaluate measurements of cerebral head circumference, biparietal diameter, body biometry, and interval growth between research scans. Fetal head circumference z-scores will be calculated from US measurements based on gestational age using the Hadlock method.

  10. Infant neuroimaging (Magnetic resonance imaging [MRI] and ultrasound) analysis [ Time Frame: Child age: Between 2-8 weeks ]
    At 2-8 weeks of age, infants will have an unsedated brain MRI and a cranial ultrasound scan. Based on investigator experience, the majority of infants can have a successful brain MRI without sedation at <6 weeks of age. The brain MRI protocol will be the standard clinical infant protocol at Children's National Hospital that includes T1, T2, susceptibility weighted imaging, and diffusion sequences. The brain MRI is without contrast.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Pregnant participants with confirmed Borrelia burgdorferi infection or diagnosed PTLDS/Chronic Lyme will be enrolled during any trimester of pregnancy. All live-born infants will be followed to age 18 months and included in the study regardless of birth outcomes.
Criteria

Inclusion Criteria:

  • English speaker
  • Currently reside in the United States or Canada
  • Meet CDC criteria for: (1) clinical and/or laboratory diagnosis of Lyme disease during any stage of current pregnancy, OR (2) clinical diagnosis of PTLDS/Chronic Lyme within 3 years of current pregnancy
  • Able to be contacted for follow-up

Exclusion Criteria:

  • Intellectually unable to comprehend study procedures
  • Health issues or metallic implant that precludes undergoing MRI
  • Incapable of completing study requirements (note: inability to travel to Children's National for in-person follow-up [for example, due to bedrest, travel restrictions, or financial inability to travel] is NOT an exclusion criterion; any interested and eligible participants requiring "remote only" participation will be permitted to join the study and complete all requirements besides in-person follow-up)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06026969


Contacts
Layout table for location contacts
Contact: Meagan Williams, MSPH, CCRC 202-476-3388 mewilliams@childrensnational.org
Contact: Sarah Mulkey, MD, PhD sbmulkey@childrensnational.org

Locations
Layout table for location information
United States, District of Columbia
Children's National Hospital Recruiting
Washington, District of Columbia, United States, 20010
Contact: Meagan Williams, MSPH, CCRC    202-476-3388    mewilliams@childrensnational.org   
Principal Investigator: Sarah B. Mulkey, MD, PhD         
Sub-Investigator: Roberta L. DeBiasi, MD, MS         
Sponsors and Collaborators
Children's National Research Institute
Clinical Trials Network for Lyme and Other Tick-Borne Diseases
Steven & Alexandra Cohen Foundation
Investigators
Layout table for investigator information
Principal Investigator: Sarah Mulkey, MD, PhD Children's National Research Institute
Additional Information:
Layout table for additonal information
Responsible Party: Children's National Research Institute
ClinicalTrials.gov Identifier: NCT06026969    
Other Study ID Numbers: 00000425
First Posted: September 7, 2023    Key Record Dates
Last Update Posted: September 7, 2023
Last Verified: September 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lyme Disease
Post-Lyme Disease Syndrome
Pregnancy Complications
Female Urogenital Diseases and Pregnancy Complications
Tick-Borne Diseases
Urogenital Diseases
Gram-Negative Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses
Infections
Borrelia Infections
Spirochaetales Infections
Vector Borne Diseases
Post-Infectious Disorders
Chronic Disease
Disease Attributes
Pathologic Processes